

Ref: Syn/CS/SE/BM/2024-25/Jan/03

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T+91 80 6891 8000

T +91 80 6891 8000 F +91 80 6891 8808

CIN: L85110KA1993PLC014937 www.syngeneintl.com

January 13, 2025

To,	То,
The Manager,	The Manager,
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Subject: Intimation of Board Meeting

Dear Sir/Madam,

Pursuant to regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, January 23, 2025, inter alia, to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ending December 31, 2024, amongst other routine matters.

Pursuant to the above, the trading window for dealing in securities of the Company for all Insiders has been closed from January 01, 2025 till the close of trading hours of January 25, 2025 (i.e. until 48 hours after the declaration of financial results), in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 as well as Company's code of conduct for Prevention of Insider Trading & Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information

The Company will organize a conference call for analysts and investors on Thursday, January 23, 2025. The details of the same will be available on the Company's website closer to the scheduled event.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra

Head Legal, Company Secretary & Compliance Officer